Janus Henderson Group

Janus Henderson Group Portfolio holdings

AUM $204B
1-Year Return 26.64%
 

Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.

This Quarter Return
+13.59%
1 Year Return
+26.64%
3 Year Return
+125.28%
5 Year Return
+196.8%
10 Year Return
+578.78%
AUM
$168B
AUM Growth
+$15B
Cap. Flow
-$3.42B
Cap. Flow %
-2.04%
Top 10 Hldgs %
26.63%
Holding
2,657
New
98
Increased
642
Reduced
1,760
Closed
111

Sector Composition

1 Technology 32.59%
2 Healthcare 19.51%
3 Consumer Discretionary 9.8%
4 Industrials 9.76%
5 Financials 9.76%
Name Market Value Portfolio Weight Shares or Principal Shares
Change %
Capital Flow
EBS icon
2576
Emergent Biosolutions
EBS
$407M
-20,359
Closed -$69.3K
EGHT icon
2577
8x8 Inc
EGHT
$269M
-47,012
Closed -$118K
EPM icon
2578
Evolution Petroleum
EPM
$175M
-12,767
Closed -$87.3K
EVGO icon
2579
EVgo
EVGO
$509M
-31,765
Closed -$108K
EXFY icon
2580
Expensify
EXFY
$177M
-21,545
Closed -$69.9K
FATE icon
2581
Fate Therapeutics
FATE
$112M
-33,963
Closed -$72.2K
FF icon
2582
Future Fuel
FF
$172M
-11,160
Closed -$80K
GLUE icon
2583
Monte Rosa Therapeutics
GLUE
$303M
-23,743
Closed -$114K
ISPO icon
2584
Inspirato
ISPO
$36.5M
-72,031
Closed -$850K
ITOS
2585
DELISTED
iTeos Therapeutics
ITOS
-500,324
Closed -$5.48M
KVYO icon
2586
Klaviyo
KVYO
$9.34B
-500,018
Closed -$17.3M
LPSN icon
2587
LivePerson
LPSN
$86.3M
-28,607
Closed -$111K
LPTX icon
2588
Leap Therapeutics
LPTX
$11.7M
-358,060
Closed -$423K
LXFR icon
2589
Luxfer Holdings
LXFR
$361M
-12,128
Closed -$158K
OSPN icon
2590
OneSpan
OSPN
$583M
-14,458
Closed -$155K
PRME icon
2591
Prime Medicine
PRME
$606M
-120,946
Closed -$1.15M
PROK icon
2592
ProKidney
PROK
$310M
-18,793
Closed -$86.2K
LXRX icon
2593
Lexicon Pharmaceuticals
LXRX
$389M
-29,470
Closed -$32K
MBI icon
2594
MBIA
MBI
$400M
-21,349
Closed -$154K
MCRB icon
2595
Seres Therapeutics
MCRB
$165M
-140,677
Closed -$6.7M
METCB icon
2596
Ramaco Resources Class B
METCB
$1.08B
-36,761
Closed -$428K
MLYS icon
2597
Mineralys Therapeutics
MLYS
$2.2B
-665,717
Closed -$6.34M
MRSN icon
2598
Mersana Therapeutics
MRSN
$35.5M
-1,226
Closed -$38.8K
NAMS icon
2599
NewAmsterdam Pharma
NAMS
$2.89B
-434,912
Closed -$3.97M
NRIX icon
2600
Nurix Therapeutics
NRIX
$697M
-12,933
Closed -$102K